Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics

K. J. Harrington, R. G. Vile, A. Melcher, J. Chester, H. S. Pandha

Research output: Contribution to journalReview articlepeer-review

65 Scopus citations


It is time for those working on oncolytic viruses to take stock of the status of the field. We now have at our disposal an array of potential therapeutic agents, and are beginning to conduct early-phase clinical trials in patients with relapsed/metastatic cancers. By drawing on lessons learned during the development of other biological therapies, such as monoclonal antibodies and targeted small molecule inhibitors, we are now in a position to chart the course of the next wave of trials that will go beyond the phase I studies of safety and feasibility. In this article we review our approach to the development of oncolytic viruses as cancer therapeutics. In doing so, we emphasise the fact that this process is modular and involves multiple iterative steps between the laboratory and the clinic. Ultimately, at least in the medium term, the future of oncolytic virotherapy lies in combination regimens with standard anti-cancer agents such as radiation and chemotherapy.

Original languageEnglish (US)
Pages (from-to)91-98
Number of pages8
JournalCytokine and Growth Factor Reviews
Issue number2-3
StatePublished - Apr 2010


  • Chemotherapy
  • Clinical trial
  • Oncolytic virus
  • Radiotherapy
  • Reovirus

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics'. Together they form a unique fingerprint.

Cite this